Adverse drug reactions in hospitals: A narrative review

Current Drug Safety

Volumn 2, Issue 1, 2007, Pages 79-87

  Davies, Emma C ^a,c   Green, Christophe F ^b   Mottram, David R ^c   Pirmohamed, Munir ^a,d  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b Countess of Chester NHS Foundation Trust ^*  (United Kingdom)

^c LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Adverse drug reactions; Hospitals

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; CARDIOVASCULAR AGENT; CLOZAPINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C9; DIAZEPAM; DIGITALIS; DIGOXIN; DIURETIC AGENT; HERBACEOUS AGENT; INSULIN; MORPHINE; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PERINDOPRIL; POTASSIUM CHANNEL BLOCKING AGENT; REMOXIPRIDE; SEROTONIN UPTAKE INHIBITOR; SOTALOL; WARFARIN;

AGE; ANAMNESIS; APLASTIC ANEMIA; AUTOMATION; CAUSE OF DEATH; CHILD HEALTH CARE; CLINICAL FEATURE; COGNITIVE DEFECT; COMPUTER SYSTEM; DATA ANALYSIS; DECISION SUPPORT SYSTEM; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG CLEARANCE; DRUG FATALITY; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; DRUG USE; ECONOMIC ASPECT; ELDERLY CARE; EPIDEMIOLOGICAL DATA; FALLING; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INCIDENCE; INFORMATION PROCESSING; INTERPERSONAL COMMUNICATION; KIDNEY FUNCTION; LENGTH OF STAY; MEDICAL DOCUMENTATION; MEDICAL INFORMATION SYSTEM; MEDICAL RESEARCH; MEDICATION ERROR; METHODOLOGY; MYOCARDITIS; PATIENT MONITORING; PATIENT SELECTION; PHARMACOGENOMICS; POLYPHARMACY; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; RISK FACTOR; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT; VOLUNTARY REPORTING;

AGE FACTORS; AGED; ANIMALS; HOSPITALS; HUMANS; LENGTH OF STAY; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; RISK FACTORS; TERMINOLOGY AS TOPIC;

EID: 34248200576     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607779315507     Document Type: Review

References (119)

1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; ii: 1358.
2. British Broadcasting Corporation. http://news.bbc.co.uk/1/hi/health/ 3704640.stm. Arthritis drug removed for safety. Accessed 21/07/2006.
3. British Broadcasting Corporation. http://www.bbc.co.uk/pressoffice/ pressreleases/stories/2003/05ȳ/11/panorama↘roxat.shtml. Seroxat suicides may be more than double that reported to Government regulator. Accessed 21/07/2006.
4. Lazarou J, Pomeranz BH, Corey PN. Incidence of Adverse Drug Reactions in Hospitalized patients. A meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205.
5. Kvasz M, Allen IE, Gordon MJ, et al. Adverse drug reactions in hospitalised patients: A critique of a meta-analysis. Medscape Gen Med 2000; 2: E3.
6. Wiffen P, Gill M, Edwards J, Moore A. Adverse drug reactions in hospital patients. A systematic review of the prospective and retrospective studies. Bandolier Extra 2002; 1-16.
7. Cluff LE, Thornton GF, Seidl LG. Studies on the epidemiology of adverse drug reactions: I. Methods of surveillance. JAMA 1964; 188: 976-983.
8. Ogilvie RI, Ruedy J. Adverse drug reactions during hospitalization. Can Med Ass J 1967; 97: 1450-1457.
9. WHO. International drug monitoring - the role of the national centers, Tech Rep ser VMO 1972, no 498.
10. Leach S, Roy SS. Adverse drug reactions: an investigation on an acute geriatric ward. Age and Ageing 1986; 15: 241-246.
11. Classen DC, Pestonik SL, Scott Evans R, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. JAMA 1997; 277: 301-306.
12. Vargas E, Terleira A, Hernando F, et al. Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit care med 2003; 31(3): 694-698.
13. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-1259.
14. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-19.
15. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997; 277: 307-311.
16. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, ed. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977: 10.
17. Grahame-Smith DG, Aronson JK. Adverse Drug Reactions. In: The Oxford Textbook of Clinical Pharmacology and drug therapy. Oxford: Oxford University Press, 1984: 132-157.
18. Hartigan-Go KY, Wong JQ. Inclusion of therapeutic failures as adverse drug reactions. In: Aronson JK, Ed. Side effects of drugs, annual 23. A worldwide annual survey of new data and trends in adverse drug reactions. Amsterdam: Elsevier, 2000; 17-33.
19. Aronson JK. Drug Therapy. In: Haslett C, et al, Eds. Davidson's Principles and Practice of Medicine. 19th Edition. London: Churchill Livingstone, 2002: 148-164.
20. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003; 327: 1222-5.
21. Howard RL, Avery AJ, Howard PD, Partridge M. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care 2003; 12: 280-285.
22. Seidl LG, Thornton GF, Cluff LE. Epidemiological studies of adverse drug reactions. Am J Public Health 1965; 65: 1170-1175.
23. Smith JW, Seidl LG, Cluff LE. Studies on the epidemiology of adverse drug reactions. V - Clinical factors influencing susceptibility. Ann Int Med 1966; 65: 629-639.
24. Hurwitz N, Wade OL. Intensive hospital monitoring of adverse reactions to drugs. BMJ 1969; 1: 531-536.
25. Simmons C, Georgeson EM, Hill RC. Adverse drug reactions: Can we reduce the risk? Hosp Pharm 1998; 33: 1568-1576.
26. Bowman L, Cardstedt BC, Hancock EF, Black CD. Adverse drug reaction(ADR) occurrence and evaluation in elderly in-patients. Pharmacoepidemiol Drug saf 1996; 5: 9-18.
27. Van Kraaij DJ, Haagsma CJ, Go IH, Gribnau FW. Drug use and adverse drug reactions in 105 elderly patients admitted to a general medical ward. Neth J Med 1994; 44(5): 166-73.
28. Medicines and Healthcare Products Regulatory Authority. Yellow Card Scheme http://www.mhra.gov.uk/home/idcplg?IdcService= SS_GET_PAGE&nodeId=276 Accessed 05/09/2006.
29. Rawlins MD. Pharmacovigilance: paradise, lost, regained or postponed. JR Coll Physicians Lond 1995; 29(1): 41-49.
30. World Health Organisation. Uppsala Monitoring Centre. http://www.who-umc.org/DynPage.aspx?id=13106&mn=1508#WHOProg Accessed 05/09/2006.
31. Venulet J, Ten Ham M. Methods for monitoring and documenting adverse drug reactions. Ent J Clin Phar Ther 1996; 34: 112-129.
32. Burgess CL, D'Arcy C, Holman J, Satti AG. Adverse drug reactions in older Australians. Medical Journal of Australia 2005; 182(6): 267-270.
33. Waller P, Shaw M, Ho D, Shakir S, Ebrahim S. Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics(HES) database. Br J Clin Pharmacol 2005; 49: 213-219.
34. Cox AR, Anton C, Goh CHF, Easter M, Langford NJ, Ferner RE. Adverse drug reactions in patients admitted to hospital identified by discharge ICD-10 codes and by spontaneous reports. Br J Clin Pharmacol 2001; 52: 337-339.
35. Azaz-Livshits T, Levy M, Sadan B, Shalit M, Geisslinger G, Brune K. Computerised surveillance of adverse drug reactions in hospital: pilot study. Br J Clin Pharmacol 1998; 45: 309-314.
36. The use of the WHO-UMC system for standardized case causality assessment. www.who-umc.org/pdfs/Casuality.pdf. Accessed 18th March 2005.
37. Karch FE, Lasagna L. Towards the operational assessment of adverse drug reactions. Clin Pharmacol Ther 1977; 21(3): 247-254.
38. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45.
39. Jones JK. Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting. Fam Comm Health 1982; 5: 58-67.
40. Tallarida RJ, Murray RB, Eiben C. A scale for assessing the severity of diseases and adverse drug reactions. Clin Phar Ther 1979; 25(4): 381-390.
41. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229-32.
42. Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990; 228: 83-90.
43. Schumock GT, Thornton JP. Focusing on the Preventability of Adverse Drug Reactions. Hosp Pharm 1992; 27: 538.
44. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2006 In Press.
45. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2003; 57(1): 6-14.
46. Anantharajau A, Feller A, Chedid A. Aging Liver. A review. Gerontology 2002; 48: 342-53.
47. Castleden CM, George CF. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 1979; 25: 297-305.
48. Todd PA, Fitton A. Perindopril. A Review of its pharmacological properties and therapeutic use. Drugs 1991; 42: 90-114.
49. Gurwitz J, Avorn J. The ambiguous relationship between aging and adverse drug reactions. Ann Int Med 1991; 114: 956-966.
50. Seidl LG, Thornton GF, Smith JW, Cluff LE. Studies on the epidemiology of adverse drug reactions. III. Reactions in patients on a general medical service. John Hopkins Med J 1966; 119: 299-315.
51. Moore N, Leocointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol 1998; 45: 301-308.
52. Bowman L, Carlstedt BC, Black CD. Incidence of adverse drug reactions in adult medical inpatients. Can J Hosp Pharm 1994; 47(5): 209-216.
53. Van den Bernt PMLA, Egberts ACG, Lenderink AW, et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci 2000; 22(2): 62-66.
54. Onder G, Gambassi G, Scales C, et al. Adverse drug reactions and cognitive function among hospitalized older adults. Eur J Clin Pharmacol 2002; 58: 371-377.
55. Carbonin P, Pahor M, Bernabei R, Sgadari A. Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Society 1991; 39: 1093-1099.
56. Caamano F, Pedone C, Zuccala G, Carbonin P. Socio-demographic factors related to the prevalence of adverse drug reaction at hospital admission in an elderly population. Arch Geron Geriatr 2005; 40: 45-52.
57. Hallas J, Worm J, Beck-Nielsen J, et al. Drug related events and drug utilization in patients admitted to a geriatric hospital department. Dan Med Bull 1991; 38: 417-20.
58. Mannesse CK, Derkx FH, De Ridder MAJ, Man in't Veld AJ, van der Cammen TJM. Do older hospital patients recognize adverse drug reactions? Age and Ageing 2000; 29(1): 79-81.
59. Gurwitz JH. Polypharmacy - A new paradigm for quality drug therapy in the elderly. Arch Int Med 2004; 164: 1957-1959.
60. Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999; 33: 236-40.
61. Nguyen JK, Fouts MF, Kotabe SE. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 2006; 4(1): 36-41.
62. Routledge PA, O'Mahony MS, Woodhouse KW. Adverse drug reactions in elderly patients. Br J Clin Pharmacol 2003; 57: 121-6.
63. Douchet J, Chassagne P, Trivalle C, et al. Drug-drug interactions related to hospital admissions in older adults: a prospective study of 1000 patients. J Am Ger Soc 1996; 44: 944-8.
64. Lindley CM, Tully MP, Paramsothy V, et al. Inappropriate medication is a major cause of adverse drug reactions in elderly patients. Age Ageing 1992; 21: 294-300.
65. Corsonello A, Pedone C, Coroca F, Mussi C, Carbonin P, Incalzi RA. Concealed renal insufficiency and adverse drug reactions in elderly hospitalised patients. Arch Int Med 2005; 165: 790-795.
66. Fattinger K, Roos M, Veregeres P, et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 49: 158-167.
67. Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. Drugs 1995; 50: 1-6.
68. Drici M-D, Clement N. Is gender a risk factor for adverse drug reactions? Drug safety 2001; 24: 575-585.
69. Schwartz JB. The influence of sex on pharmacokinetics. Clin pharmacokinet 2003; 42(2): 107-121.
70. Lehmann MH, Hardy S, Archibald D, MacNeil DJ. JTc Prolongation with d, 1-sotalol in women versus men. Am J Cardiol 1999; 83(3): 354-9.
71. Roden DM. Drug-induced prolongation of the QT interval. New Engl J Med 2004; 350(10): 1013-1022.
72. Piazza LA, Markowitz JC, Kocsis JH, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants. Am J Psychiatry 1997; 154: 1757-65.
73. Danielson DA, Porter JB, Dinan BJ, et al. Drug monitoring of surgical patients. JAMA 1982; 248(12): 1482-1485.
74. Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmonson A, Leape LL. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 1997; 25: 1289-1297
75. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 1995; 274: 29-34.
76. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52(1): 77-83.
77. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 1999; 88: 965-8.
78. Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 2002; 54: 665-670.
79. Fattahi F, Pourpak Z, Moin M, et al. Adverse drug reactions in hospitalised children in a department of infectious diseases. J Clin Pharmacol 2005; 45: 1313-1318.
80. Schimmel EM. The Hazards of Hospitalization. Ann Intern Med. 1964; 60(1): 100-110.
81. Onder G, Penninx BWJH, Landi F, et al. Depression and adverse drug reactons among hospitalized older adults. Arch Int Med 2003; 163: 301-5.
82. Dartnell JGA, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. MJA 1996; 164: 659-662.
83. Green CF, Mottram DR, Rowe PH, Pirmohamed M. Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study. J Clin Pharm Ther 2000; 25: 355-361.
84. Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Drug-related hospital admissions: a review of Australian studies published 1988-1996. MJA 1998; 168: 405-408.
85. Beijer HJM, Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy World and Science 2002; 24(2): 46-54.
86. Collins DJ, Nickless GD, Green CF. Medication histories: does anyone know what medicines a patient should be takine. Int J Pharm Prac 2004; 12(4): 173-178.
87. Cockayne NL, Duguid M, Shenfield GM. Health professionals rarely record history of complementary and alternative medicines. Br J Clin Pharmacol 2004; 59(2): 254-258.
88. Hughes L, Whittlesea C, Luscombe D. Patients' knowledge and perceptions of the side-effects of OTC medication. J Clin Phar Ther 2002; 27: 243-248.
89. Scottish Intercollegiate Guidelines Network http://www.sign.ac.uk/ guidelines/fulltext/41/section5.html. Secondary Prevention of Coronary Heart Disease following Myocardial Infarction. Section 5: Pharmacological intervention following MI. Accessed 10/02/2006.
90. Evans RS, Pestotnik SL, Classen DC, Horn SD, Bass SB, Burke JP. Preventing adverse drug events in hospitalized patients. Ann Pharmacother 1994; 28: 523-7.
91. Suh D-C, Woodall BS, Shin S-K, Hermes-De Santis. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000; 34: 1373-9.
92. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalization. Drug Saf 2000; 22(2): 161-8.
93. Spino M, Sellers EM, Kaplan HL. Effect of adverse drug reactions on the length of hospitalization. Am J Hosp Pharm 1978; 35: 1060-1064.
94. Bordet R, Gautier S, LeLouet H, Dupuis B, Caron J. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J Clin Pharmacol 2001; 56: 935-941.
95. McDonnell PJ. The $181,000 adverse drug reaction. Hospital Pharmacy 2004; 39(7): 648-652.
96. Lundkvist J, Jonsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 2004; 18: 275-80.
97. Pearson TF, Pittman DG, Longley JM, Grapes ZT, Vigliotti DJ, Mullis SR. Factors associated with preventable adverse drug reactions. Am J Hosp Pharm 1994; 51: 2268-2272.
98. Leape LL, Lawthers AG, Brennan TA, et al. Preventing medical injury. Qual Rev Bull 1993; 8: 144-149.
99. Seeger JD, Schumock GT, Kong SX. Estimating the rate of adverse drug reactions with capture-recapture analysis. Am J Health-Sys Pharm 1996; 53: 178-181.
100. Leape LL, Cullen DJ, Dempsey Clapp M, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282: 267-270.
101. Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med 2003; 163: 2014-2018.
102. Seeger JD, Kong SX, Schumock GT. Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients. Pharmacotherapy 1998; 18(6): 1284-1289.
103. Lee A, Rawlins MD. Adverse drug reactions. In: Walker R, Edwards C, Eds. In Clinical Pharmacy and Therapeutics 3rd edition. London, Churchill Livingstone. 2002; 33-46.
104. Raschke RA, Gollihare B, Wunderlich TA, et al. A computer alert system to prevent injury from adverse drug events. JAMA 1998; 280(15): 1317-20.
105. Dormann H, Criegee-Rieck M, Neubert A, et al. Implementation of a computer-assisted monitoring system for the detection of adverse drug reactions in gastroenterology. Ailment Pharmacol Ther 2004; 19: 303-9.
106. Levy M, Azaz-Livshits T, Sadan B, Shalit M, Gesslinger G, Brune K. Computerised surveillance of adverse drug reactions in hospital: Implementation. Eur J Clin Pharmacol 1999; 54: 887-892.
107. Gosney M, Tallis R. Prescription of contraindicated and interacting drugs in elderly patients admitted to hospital. Lancet 1984; 2: 564-567.
108. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289(13): 1652-1658.
109. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes. Ann Intern Med 1996; 124: 884-90.
110. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 2003; 58: 773-778.
111. Dean B, Schachter M, Vincent C, Barber N. Causes of prescribing errors in hospital inpatients: a prospective study. Lancet 2002; 359: 1373-8.
112. Altman RB, Klein TE. Challenges for biomedical informatics and pharmacogenomics. Ann Rev Pharmacol Toxicol 2002; 42: 113-33.
113. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired(s) - warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
114. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719.
115. Pirmohamed M, Park BK. Adverse drug reactions: back to the future. Br J Clin Pharmacol 2003; 55: 486-492.
116. Wilkinson GR. Drug Metabolism and Variability among Patients in Drug Response. NEJM 2005; 352(21): 2211-2224.
117. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenetics in reducing adverse drug reaction. JAMA 2001; 286: 2270-2279.
118. Meyer U. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-71.
119. Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22(6): 298-305.